264 related articles for article (PubMed ID: 29886021)
21. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
[TBL] [Abstract][Full Text] [Related]
22. Arene-Ru(II) complexes of curcumin exert antitumor activity via proteasome inhibition and apoptosis induction.
Bonfili L; Pettinari R; Cuccioloni M; Cecarini V; Mozzicafreddo M; Angeletti M; Lupidi G; Marchetti F; Pettinari C; Eleuteri AM
ChemMedChem; 2012 Nov; 7(11):2010-20. PubMed ID: 22997162
[TBL] [Abstract][Full Text] [Related]
23. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome.
Achanta G; Modzelewska A; Feng L; Khan SR; Huang P
Mol Pharmacol; 2006 Jul; 70(1):426-33. PubMed ID: 16636137
[TBL] [Abstract][Full Text] [Related]
24. Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Zhou Y; Liu X; Xue J; Liu L; Liang T; Li W; Yang X; Hou X; Fang H
J Med Chem; 2020 May; 63(9):4701-4715. PubMed ID: 32267687
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
Niroula D; Hallada LP; Le Chapelain C; Ganegamage SK; Dotson D; Rogelj S; Groll M; Tello-Aburto R
Eur J Med Chem; 2018 Sep; 157():962-977. PubMed ID: 30165344
[TBL] [Abstract][Full Text] [Related]
26. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
28. Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
Kawamura S; Unno Y; Asai A; Arisawa M; Shuto S
J Med Chem; 2014 Mar; 57(6):2726-35. PubMed ID: 24524217
[TBL] [Abstract][Full Text] [Related]
29. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X
Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
Zhang W; Wang X; Zhang H; Wen T; Yang L; Miao H; Wang J; Liu H; Yang X; Lei M; Zhu Y
Bioorg Med Chem; 2021 Jun; 40():116182. PubMed ID: 33971487
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
32. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
[TBL] [Abstract][Full Text] [Related]
33. Biological activity, design, synthesis and structure activity relationship of some novel derivatives of curcumin containing sulfonamides.
Lal J; Gupta SK; Thavaselvam D; Agarwal DD
Eur J Med Chem; 2013 Jun; 64():579-88. PubMed ID: 23685942
[TBL] [Abstract][Full Text] [Related]
34. Novel Curcumin Inspired Antineoplastic 1-Sulfonyl-4-Piperidones: Design, Synthesis and Molecular Modeling Studies.
Fawzy NG; Panda SS; Fayad W; El-Manawaty MA; Srour AM; Girgis AS
Anticancer Agents Med Chem; 2019; 19(8):1069-1078. PubMed ID: 30961509
[TBL] [Abstract][Full Text] [Related]
35. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.
Cheemanapalli S; Anuradha CM; Madhusudhana P; Mahesh M; Raghavendra PB; Kumar CS
Anticancer Agents Med Chem; 2016; 16(11):1496-1510. PubMed ID: 27173965
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors.
Yang Y; Wang K; Wu B; Yang Y; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2020 Nov; 30(21):127508. PubMed ID: 32853683
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of 1,5-bis(4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one and its aminomethyl derivatives.
Yerdelen KO; Gul HI; Sakagami H; Umemura N
J Enzyme Inhib Med Chem; 2015 Jun; 30(3):383-8. PubMed ID: 25068729
[TBL] [Abstract][Full Text] [Related]
38. Development of peptide epoxyketones as selective immunoproteasome inhibitors.
Li X; Hong D; Zhang M; Xu L; Zhou Y; Li J; Liu T
Eur J Med Chem; 2021 Oct; 221():113556. PubMed ID: 34087498
[TBL] [Abstract][Full Text] [Related]
39. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.
Agyin JK; Santhamma B; Roy SS
Bioorg Med Chem Lett; 2013 Dec; 23(23):6455-8. PubMed ID: 24119559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
